Document:

NEW SECURITY AGREEMENT

 

THIS NEW
SECURITY AGREEMENT (together with all exhibits, this “Security Agreement”) is made as of October 31, 2007
by and between Intracel Holdings Corporation, as the grantor (the “Grantor”) and Organon BioSciences
International B.V. (as successor in interest to Akzo Nobel Pharma International B.V.) and Organon Teknika Corporation (the
“Secured Parties”). All terms capitalized but not otherwise defined herein shall have the meanings
ascribed to them in the Letter Agreement (as defined below).

 

Under the terms hereof,
the Secured Parties desire to obtain and the Grantor desires to grant the Secured Parties security for all of the Obligations (as
hereinafter defined).

 

NOW, THEREFORE, the
Grantor and the Secured Parties, intending to be legally bound, hereby agree as follows:

 

1.          Definitions.

 

(a)          “Collateral”
means, unless and until the events described in the following sentence occur, those certain patents and patent applications set
forth in Exhibit A, attached hereto, that are labeled in Exhibit A as having been previously owned by Organon (including, without
limitations, all divisions, continuations, continuations in part, reissues, renewals or extensions thereof) (the “Organon
Patents”). Solely if (i) Vaccinogen makes, on behalf of Intracel, the payment set forth in Section 3.1(a)(i) of the Letter
Agreement, as required by the Vaccinogen License, and otherwise complies with all requirements in the Vaccinogen License necessary
for the license granted to Vaccinogen thereunder to become effective, or (ii) Vaccinogen fails to comply with such requirements
and Intracel elects to cure such failure in accordance with Sections 5(a) and 5(b) of the Letter Agreement, then the Collateral
shall thereafter mean (A) the Organon Patents; (B) all other patents and patent applications set forth in Exhibit A, attached hereto
(including, without limitations, all divisions, continuations, continuations in part, reissues, renewals or extensions thereof)
(the “Intracel Patents”), (C) certain trademarks set forth on Exhibit B, attached hereto (including all goodwill connected
with the use of, and symbolized by, any and all such trademarks), and (D) any other ownership and/or license rights of Grantor
in the Onco Vax Program. For clarity, the Collateral shall not include any rights in real property.

 

(b)          “Obligations”
means Grantor’s obligation to satisfy its obligations in connection with the Current Liabilities (as defined in the Letter
Agreement) under Section 3(a) of the Letter Agreement, and all reasonable costs and expenses of the Secured Parties incurred in
the enforcement or collection of such obligation, including but not limited to reasonable attorneys’ fees and expenses.

 

(c)          “Letter
Agreement” means the Letter Agreement dated as of the date hereof by and between the Grantor and the Secured Parties,
including all riders, exhibits and schedules thereto, as the same may be amended from time to time.

 

(d)          “Escrow
Agreement” means that certain Escrow Agreement among Grantor, Secured Parties and Escrow Agent, a form of which is attached
hereto as Exhibit C.

 

    	1.

    	 

    

 

(e)          “Escrow
Agent” means the party serving as escrow agent under the Escrow Agreement.

 

(f)        “OncoVax
Program” means all assets or property owned or controlled by Grantor relating to its OncoVax Active Specific Immunotherapy
technology platform and related human monoclonal antibody products, including, but not limited to, all know-how, NDAs, and patent
rights, related to and/or necessary to commercially exploit the OncoVax Program. For clarity, the OncoVax Program shall exclude
the Excluded Assets (including any know-how, NDAs, or patents that are associated with or claim the Excluded Assets).

 

(g)          “Excluded
Assets” means any and all of the following and any other assets or properties that are specifically associated therewith:
(a) the Xoma material transfer agreement dated as of January 29, 2007 (b) the Exclusive License Agreement between Intracel and
Oxigene, Inc., dated as of March 30, 2007; (c) the KLH and CVD reagent business and associated intellectual property; and (d) materials,
know-how, research data, patents and patent applications covering HumaCD4, HumaRESP, AntiCD38, HumaSTAPH and HumaENT, or any human
antibody that has been isolated by or on behalf of Intracel from phage display libraries.

 

(h)          “Permitted
Lien” means: (i) liens or other encumbrances for taxes, fees, assessments or other governmental charges or levies, either
not delinquent or being contested in good faith by appropriate proceedings; (ii) liens or other encumbrances (A) upon or in any
equipment acquired or held by Grantor to secure the purchase price of such equipment or indebtedness incurred solely for the purpose
of financing the acquisition of such equipment or (B) existing on such equipment at the time of its acquisition, provided that
the lien is confined solely to the equipment so acquired, improvements thereon and/or the proceeds of such equipment; (iii) licenses
or sublicenses (whether express or implied) granted to distributors in connection with the sale of inventory in the ordinary course
of business or granted to end users of products with respect to the use of such products; (iv) liens or other encumbrances arising
solely by virtue of any statutory or common law provision relating to banker’s liens, rights of setoff or similar rights
and remedies as to deposit accounts or other funds maintained with a creditor depository institution; and (v) any liens securing
debt issued in connection with investments in Intracel, its affiliates, or Vaccinogen, provided that such liens comply with the
last sentence of Section 6 (whether as a result of priority rules, subordination, or otherwise). All liens that, as of the Effective
Date, fall within the category of Permitted Liens described in subsection (v) above are listed in Exhibit G.

 

(i)          “Vaccinogen”
means Vaccinogen, Inc.

 

(j)          “Vaccinogen
License” has the meaning set forth in the Letter Agreement.

 

2.          Grant
of Security Interest. To secure the Obligations, the Grantor hereby assigns and grants to the Secured Parties, as Secured
Parties, a continuing lien on and security interest in the Collateral.

 

3.          Change
in Name. The Grantor hereby agrees that if the Grantor changes its name or form of organization, the Grantor will promptly
notify the Secured Parties in writing of the changes.

 

    	2.

    	 

    

 

4.          Representations
and Warranties. The Grantor represents, warrants and covenants to the Secured Parties that, other than the Permitted Liens
and the transaction with Vaccinogen described in the Letter Agreement: (a) the Grantor has not made any prior pledge, encumbrance,
assignment or other disposition of any of the Collateral and the same are free from all encumbrances and rights of setoff of any
kind; and (b) the Grantor will defend the Collateral against all claims and demands of all persons at any time claiming any interest
therein that is in conflict with the security interest granted to the Secured Parties herein.

 

5.          Grantor’s
Covenants. The Grantor covenants that it shall:

 

(a)          do,
obtain, make, execute and deliver all such additional and further acts, things, deeds, assurances and instruments as the Secured
Parties may reasonably require to vest in and assure to the Secured Parties its rights hereunder and in or to the Collateral;

 

(b)          to
the extent applicable, keep the Collateral in good order and repair at all times, normal wear and tear excepted, or, if Grantor
so elects, replace the Collateral with items of similar use and value; and

 

(c)          only
use or permit the Collateral to be used in material compliance with all applicable federal, state, county and municipal laws and
regulations.

 

6.          Negative
Pledge; No Transfer. Except for the Permitted Liens or the transaction with Vaccinogen described in the Letter Agreement
and except in connection with the sale of inventory in the ordinary course of business, the Grantor will not sell or offer to sell
or otherwise transfer or grant or suffer the imposition of any security interest upon the Collateral or use any portion thereof
in any manner inconsistent with Grantor’s obligations under the Agreement. Notwithstanding anything herein or in the Vaccinogen
agreement to the contrary, Organon’s security interest (i) in the Organon Patents shall be senior to any debt issued in connection
with investments in Intracel or Vaccinogen and (ii) in all other portions of the Collateral shall be pari passu to the most senior
debt issued in connection with investments in Intracel or Vaccinogen.

 

7.          Escrow
Agent. The Grantor and the Secured Parties, along with an escrow agent mutually determined by the Grantor and Secured Parties,
shall, as promptly as reasonably practicable following the execution of this Security Agreement, execute and deliver the Escrow
Agreement in the form attached as Exhibit C hereto (or such other form of Escrow Agreement mutually agreed by the Grantor,
Secured Parties, and the escrow agent).

 

8.          Assignments.
The Grantor shall execute and deliver to the Escrow Agent (but only to the extent any of the following are included in the
Collateral): (i) the assignment of the Organon Patents, Intracel Patents and other patent applications related to the OncoVax
Program, (ii) the assignment of know how, and (iii) the NDA assignment, each in the forms attached as Exhibit D. Exhibit
E and Exhibit F hereto (together, the “Assignments”). As of the date of this Agreement, the
Grantor has executed the Assignments, and such executed Assignments will be temporarily held in escrow at the offices of
Cooley Godward Kronish LLP, until such time as the Escrow Agreement has been executed between the Grantor, the Secured
Parties, and the escrow agent.

 

9.          Intentionally
deleted.

 

    	3.

    	 

    

 

10.         Events
of Default. The Grantor shall, after receiving written notice from the Secured Parties informing Grantor either (i) that
a failure by Grantor to perform any of the Obligations has occurred (subject to Section 5 of the Letter Agreement) and that the
notice required to be given pursuant to the Letter Agreement has been given, or (ii) that the Grantor has attempted to impede the
performance by the Escrow Agent of any of its obligations under the Escrow Agreement, have a forty five (45) day period in which
to cure the default and if it does not do so cure within such period, an “Event of Default” shall be deemed
to have occurred hereunder.

 

11.         
Remedies. Upon the occurrence of any such Event of Default and at any time thereafter, the Secured Parties may declare
all outstanding Obligations secured hereby immediately due and payable upon written notice to Grantor and shall have any remedies
provided herein or by any applicable law or in equity, and shall have the unconditional right to demand of and receive from the
Escrow Agent the Assignments.

 

12.         Notices.
All notices, demands, requests, consents, approvals and other communications required or permitted hereunder must be in writing
and will be effective upon receipt if delivered personally to such party, or if sent by facsimile transmission with written confirmation
of delivery, or by nationally recognized overnight courier service, to the address set forth herein or to such other address as
any party may give to the other in writing for such purpose.

 

13.         Preservation
of Rights. No delay or omission on the part of the Secured Parties to exercise any right or power arising hereunder will
impair any such right or power or be considered a waiver of any such right or power or any acquiescence therein, nor will the action
or inaction of the Secured Parties impair any right or power arising hereunder. The Secured Party’s rights and remedies hereunder
are cumulative and not exclusive of any other rights or remedies which the Secured Parties may have under other agreements, at
law or in equity.

 

14.         Changes
in Writing. No modification, amendment or waiver of any provision of this Security Agreement nor consent to any departure
by the Grantor therefrom, will in any event be effective unless the same is in writing and signed by the Secured Parties, and then
such waiver or consent shall be effective only in the specific instance and for the purpose for which given. No notice to or demand
on the Grantor in any case will entitle the Grantor to any other or further notice or demand in the same, similar or other circumstance.

 

15.         Counterparts.
This Security Agreement may be signed in any number of counterpart copies and by the parties hereto on separate counterparts, but
all such copies shall constitute one and the same instrument.

 

16.         Successors
and Assigns. Grantor may assign this Security Agreement to a third party in connection with the transfer and assignment
of the Collateral to such party, to the extent such transfer and assignment is permitted under the Letter Agreement. This Security
Agreement will be binding upon and inure to the benefit of the Grantor and the Secured Parties and their respective successors
and assigns; provided, however, that the Grantor may not assign this Security Agreement in whole or in part except
to the extent specifically provided in the Letter Agreement, and subject to the conditions set forth therein.

 

    	4.

    	 

    

 

17.         Governing
Law and Jurisdiction. This Security Agreement will be governed by and construed under the laws of the State of New York,
applicable to contracts made and to be performed in the State of New York.

 

18.         Termination.
This Security Agreement shall terminate upon the payment and performance in full of the Obligations.

 

    	5.

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Security Agreement, as of the date first written above.

 

	 	INTRACEL HOLDINGS
	 	CORPORATION
	 	 	 
	 	By:	/s/ Mitchell Finder, CEO
	 	 	 
	 	Print Name:	Mitchell Finder, CEO
	 	 	 
	 	Title:	 
	 	 	 
	 	ORGANON TEKNIKA CORP.
	 	 	 
	 	By:	/s/ Dante Serricchio
	 	 	 
	 	Print Name:	Dante Serricchio
	 	 	 
	 	Title:	President
	 	 	 
	 	By:	/s/ A P. van Tiggelen
	 	 	 
	 	Print Name:	A P. van Tiggelen
	 	 	 
	 	Title:	VP Finance
	 	 	 
	 	ORGANON BIOSCIENCES
	 	INTERNATIONAL B.V.
	 	 	 
	 	By:	/s/ A Wilderbeek
	 	 	 
	 	Print Name:	A.T.M Wilderbeek
	 	 	 
	 	Title:	Director
	 	 	 
	 	By:	/s/ G. van Alphen
	 	 	 
	 	Print Name:	G. van Alphen
	 	 	 
	 	Title:	Director
	 	 	 
	 	 	

 

[SIGNATURE PAGE TO NEW SECURITY AGREEMENT]

 

    	6.

    	 

    

 

ALL-PURPOSE ACKNOWLEDGMENT FOR CALIFORNIA

 

	STATE OF CALIFORNIA	)
	 	)    ss.
	COUNTY OF SANTA CLARA	)

 

	On  October 26, 2007             ,
    before me,  	Wendy Seagraves. Notary Public	,
	Date	Name And Title Of Officer
    (e.g. “Jane Doe, Notary Public”)	 

  

	personally appeared    	Mitchell N. Finer	 ,
	 	Name(s) of Signer(s)	 

 

	 	 ̈       personally known to me
	 	 
	 	x       proved to me on the basis of satisfactory evidence
	 	 
	 	to be the person whose name is subscribed to the
    within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature
    on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.
	 	WITNESS my hand and official seal.
	 	 
	 	/s/ Wendy Seagraves
	Place Notary Seal Above	Signature of Notary Public

 

OPTIONAL

 

Though the information below is not
required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment
of this form to another document.

 

Description of Attached Document

 

	Title or Type of Document:	New Security Agreement Between Intracel Holdings and Organon BioSciences

 

	Document Date:	 	 Number of Pages: 	6

 

	Signer(s) Other Than Named Above:	 

 

	Capacity(ies) Claimed by Signer	 	 
	 	 	 
	Signer’s Name:	 	 	 	 
	 	 	 
	 ̈   Individual	 	Top of thumb here
	 ̈   Corporate Officer - Title(s):	 	 	 
	 ̈   Partner -  ̈ Limited  ̈ General 	 	 
	 ̈   Attorney-in-Fact	 	 
	 ̈   Trustee	 	 
	 ̈   Guardian or Conservator 	 	 
	 ̈   Other:  	 	 	 	 
	 	 	 
	Signer is representing:	 	 	 

 

    	7.

    	 

    

 

Exhibit A

 

Patents and Patent Applications in Collateral

 

	Client-Matter	 	Country	 	Status	 	Title	 	Number/Date	 	Number/Date
	I8602.0006/P006	 	US	 	F	 	STERILE IMMUNOGENIC NON-TUMORIGENIC TUMOR CELL COMPOSITIONS AND METHODS	 	
        10/370,081

        2/21/2003
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0006/P006	 	AU	 	F	 	STERILE IMMUNOGENIC NON-TUMORIENIC TUMOR CELL COMPOSITIONS AND METHODS	 	
        2003230553

        2/21/2003
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0006/P006	 	CA	 	F	 	STERILE IMMUNOGENIC NON-TUMORIENIC TUMOR CELL COMPOSITIONS AND METHODS	 	
        2,476,999

        2/21/2003
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0006/P006	 	CN	 	F	 	STERILE IMMUNOGENIC NON-TUMORIENIC TUMOR CELL COMPOSITIONS AND METHODS	 	
        03809115.1

        2/21/2003
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0006/P006	 	EP	 	F	 	STERILE IMMUNOGENIC NON-TUMORIENIC TUMOR CELL COMPOSITIONS AND METHODS	 	
        03723633.8

        2/21/2003
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0006/P006	 	SG	 	G	 	STERILE IMMUNOGENIC NON-TUMORIENIC TUMOR CELL COMPOSITIONS AND METHODS	 	
        200404941-7

        2/21/2003
	 	
        106347

        5/30/2007

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0006/P006	 	WO	 	F	 	STERILE IMMUNOGENIC NON-TUMORIENIC TUMOR CELL COMPOSITIONS AND METHODS	 	
        PCT/US03/05154

        2/21/2003
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0006/P006	 	JP	 	I	 	STERILE IMMUNOGENIC NON-TUMORIENIC TUMOR CELL COMPOSITIONS AND METHODS	 	
        570,779/2003

        2/21/2003
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0006/P006	 	US	 	D	 	STERILE IMMUNOGENIC NON-TUMORIGENIC TUMOR CELL COMPOSITIONS AND METHODS	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0006/P006	 	US	 	D	 	STERILE IMMUNOGENIC NON-TUMORIGENIC TUMOR CELL COMPOSITIONS AND METHODS	 	 	 	 

 

    	8.

    	 

    

 

The following patents were previously owned by Organon:

 

	Client-Matter	 	Country	 	Status	 	Title	 	Number/Date	 	Number/Date
	I8602.0010/P010	 	US	 	G	 	TUMOR ASSOCIATED MONOCLONAL ANTIBODIES	 	
        08/449,613

        5/24/1995
	 	
        5,474,755

        12/12/1995

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0011/P011	 	US	 	I	 	TUMOR ASSOCIATED MONOCLONAL ANTIBODY 81AV/78	 	
        08/094,589

        7/20/1993
	 	
        5,348,880

        9/20/1994

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0014/P014	 	US	 	F	 	ANTIGEN RECOGNIZED BY MCA 16-88	 	
        08/272,402

        7/7/1994
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0015/P015	 	WO	 	F	 	ANTIGEN RECOGNIZED BY MCA 16-88	 	
        PCT/US88/02245

        7/1/1988
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0029/P029	 	US	 	G	 	TUMOR SPECIFIC MONOCLONAL ANTIBODIES	 	
        645,069

        1/22/1991
	 	
        5,180,814

        1/19/1993

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0030/P030	 	US	 	G	 	TUMOR SPECIFIC MONOCLONAL	 	
        302,155

        1/25/1989
	 	
        5,106,738

        4/21/1992

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0031/P031	 	US	 	G	 	TUMOR SPECIFIC MONOCLONAL	 	
        697,078

        1/31/1985
	 	
        4,828,991

        5/9/1989

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0032/P032	 	US	 	G	 	ACTIVE SPECIFIC IMMUNOTHERAPY	 	
        07/122,257

        11/1/1993
	 	
        5,484,596

        1/16/1996

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0033/P033	 	US	 	G	 	CHELATING AGENTS FOR ATTACHING METAL IONS TO PROTEINS	 	
        08/044,875

        4/8/1993
	 	
        5,292,868

        3/8/1994

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0034/P034	 	US	 	G	 	TUMOR ASSOCIATED EPITOPE	 	
        08/960,128

        8/19/1997
	 	
        5,951,985

        9/14/1999

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0035/P035	 	US	 	G	 	ANTIGEN RECOGNIZED BY MCA 16-88	 	
        07/929,842

        8/13/1992
	 	
        5,338,832

        8/16/1994

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0036/P036	 	CA	 	G	 	TUMOR SPECIFIC MONOCLONAL ANTIBODIES	 	
        473130

        1/30/1985
	 	
        1,340,781

        1/30/1985

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0037/P037	 	CA	 	F	 	TUMOR ASSOCIATED EPITOPES	 	
        2,222,551

        6/6/1996
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0038/P038	 	PT	 	I	 	PROCESS FOR PREPARING TUMOR SPECIFIC MONOCLONAL ANTIBODIES	 	
        8579894

        1/31/1984
	 	
        79894

        1/31/1984

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0039/P039	 	JP	 	G	 	ANTIGEN RECOGNIZED BY MONOCLONAL ANTIBODY 16- 88	 	
        1988 505983

        7/1/1988
	 	
        3081208

        6/23/1989

 

    	9.

    	 

    

 

	I8602.0040/P040	 	JP	 	F	 	TUMOR ASSOCIATED EPITOPES	 	
        9-501429

        6/6/1996
	 	 
	 	 	 	 	 	 	 	 	 	 	 
	I8602.0041/P041	 	DE	 	G	 	CHELATING AGENTS FOR ATTACHING METAL IONS TO PROTEINS	 	
        9069022542

        5/23/1990
	 	
        69022542

        6/23/1991

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0042/P042	 	DE	 	G	 	TUMRO SPECIFIC MONOCLONAL ANTIBODIES	 	
        8585300610

        1/30/1985
	 	
        358093

        1/30/1985

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0043/P043	 	GB	 	G	 	TUMOR SPECIFIC MONOCLONAL ANTIBODIES	 	
        EP0151030

        1/30/1985
	 	
        8585300610

        1/30/1985

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0044/P044	 	IL	 	G	 	TUMOR SPECIFIC MONOCLONAL ANTIBODIES	 	
        92103758

        11/16/1992
	 	
        103758

        11/16/1992

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0045/P045	 	IT	 	I	 	TUMOR SPECIFIC MONOCLONAL ANTIBODIES	 	
        8585300610

        1/30/1985
	 	
        151030

        1/30/1985

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0046/P046	 	IT	 	I	 	CHELATING AGENTS FOR ATTACHING METAL IONS TO PROTEINS	 	
        9090914273

        5/23/1990
	 	
        429644

        5/23/1990

	 	 	 	 	 	 	 	 	 	 	 
	I8602.0047/P047	 	NZ	 	G	 	TUMOUR-SPECIFIC MONOCLONAL ANTIBODIES, PRODUCTION THEREOF AND USE	 	
        85210867

        1/17/1985
	 	
        210867

        1/17/1985

 

    	10.EXTENSION AND SECOND AMENDMENT
TO LEASE

 

This Extension and Second Amendment to Lease (the “Amendment”)
is made this 23 day of October, 2012, by and between Martens Properties L.L.L.P., a Maryland limited liability limited partnership
(“Landlord”) and Vaccinogen LLC (“Tenant”).

 

WITNESSETH:

 

WHEREAS, Landlord and Tenant entered
into a certain Lease, dated October 24, 2007, pursuant to which Tenant leased four thousand and sixty four (4,064) square feet,
known as Suite 406 (the “Leased Premises”), in the commercial office building known as Westview Office Court located
at 5300 Westview Drive, Frederick, Maryland 21710 (the “Building”), and

 

WHEREAS, the term of the Lease will
expire on October 31, 2012, and Landlord and Tenant desire to extend the term of the Lease and amend certain other terms and conditions
hereinafter set forth;

 

NOW THEREFORE, in consideration
of the premises and mutual covenants and agreements contained herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

1. Extension of Lease Term.
The term of the Lease is hereby extended for a period of six (6) months, commencing on November 1, 2012 (“Extension Commencement
Date”) and expiring April 30, 2013 (“Lease Expiration Date”). This First Extension Term shall be upon all the
same terms and conditions as set forth in the Lease with respect to the Initial Term thereof, except as modified herein. Tenant
will be provided one (1) additional six (6) month extension period by providing Landlord with sixty days (60) prior written notice
by February 28, 2013 (hereinafter referred to as "Second Extension Period"). In the Second Extension Period Landlord
shall have the right to terminate the lease, at any time, by providing sixty (60) days prior written notice to Tenant. All provisions
of the Lease shall govern during any extension period. .

 

2. Base Rent. As of the Extension
Commencement Date, the Base Rent amount of Five Thousand Eighty Nine and 38/100 Dollars ($5,089.38) shall be paid in equal monthly
installments.,

 

3. Additional Rent.  In addition
to paying the Base Rent specified in Paragraph 2 above, Tenant shall remain obligated to pay to Landlord the amounts determined
to be Tax Adjustment and Expense Adjustment (collectively called “Additional Rent”) upon the same terms and conditions
as set forth in the Initial Lease.

 

4. Brokers. Tenant represents
and warrants to Landlord that Tenant has not dealt with any realtor, broker, agent, or finder in connection with this Amendment
other than McShea and Company, Inc. (“Landlord’s Agent”). Tenant shall indemnify and hold Landlord harmless from
and against any loss, claim, damage, expense or liability for any compensation, commission, or charges claimed by any other realtor,
broker, agent, or finder claiming to have dealt with Tenant in connection with this Amendment.

 

5. Reaffirmation of Terms.
All other terms, covenants, and provisions of the Lease not expressly modified and amended hereby shall remain in full force and
effect, and are hereby ratified and confirmed in all respects.

  

IN WITNESS WHEREOF, the parties hereto have duly executed
this Second Amendment to Lease on the day and year first written above.

 

    	Page 1 of 2

    	 

    

 

	WITNESS	 	TENANT
		 	VACCINOGEN LLC
	 	 	 	 
	 	 	By:	/s/ Michael G. Hanna
	 	 	 	 
	 	 	Date:	23 October 2012
	 	 	 	 
	 	 	LANDLORD
	WITNESS	 	MARTENS PROPERTIES L.L.L.P.
	 	 	 	 
	 	 	By:	 
	 	 	 	 
		 	Date:	 

 

    	Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]